Neuromuscular disorders encompass a variety of diseases that impair normal function of skeletal muscle. A subset of neuromuscular disorders, the congenital myasthenic syndromes (CMSs), represent a heterogeneous group of heritable diseases caused by abnormal signal transmission at the motor endplate (EP), a synaptic connection between motor axon nerve terminals and skeletal muscle fibers (see review: Engel *et al*. [2015](#age12350-bib-0010){ref-type="ref"}). Most CMSs are autosomal recessive conditions characterized by functional or structural abnormalities of proteins localized to the presynaptic, synaptic or postsynaptic regions of the motor EP. At least 18 genes are associated with genetically distinct forms of CMS (<http://www.ncbi.nlm.nih.gov/omim/?term=congenital+myasthenic+syndromes>), encoding proteins expressed at the neuromuscular junction. Their defined molecular basis in human patients supports targeted and efficient therapies for disease management and improved prognosis (see reviews: Ohno & Engel [2003](#age12350-bib-0024){ref-type="ref"}; Mihaylova *et al*. [2008](#age12350-bib-0022){ref-type="ref"}; Engel *et al*. [2012](#age12350-bib-0009){ref-type="ref"}; Hantai *et al*. [2013](#age12350-bib-0015){ref-type="ref"}).

Variants in *collagen‐like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase* (*COLQ*) result in EP acetylcholinesterase (AchE) deficiency (EAD) and account for 10--15% of human CMS (Abicht *et al*. [2012](#age12350-bib-0001){ref-type="ref"}). A diagnostic clue to an EAD is worsening of clinical weakness with anticholinesterase drugs (Engel *et al*. [2015](#age12350-bib-0010){ref-type="ref"}). Thus, therapeutic options in humans include the adrenergic agonists ephedrine and albuterol, although mechanisms of action are not understood. Approximately 30 *COLQ* variants are currently associated with CMS (Ohno *et al*. [2000](#age12350-bib-0025){ref-type="ref"}; Engel *et al*. [2003b](#age12350-bib-0008){ref-type="ref"}; Engel & Sine [2005](#age12350-bib-0006){ref-type="ref"}; Mihaylova *et al*. [2008](#age12350-bib-0022){ref-type="ref"}).

Several animal models for neuromuscular disorders exist (Gaschen *et al*. [2004](#age12350-bib-0014){ref-type="ref"}; Shelton & Engvall [2005](#age12350-bib-0033){ref-type="ref"}). Genetically defined recessive CMS models, orthologs of human diseases, are limited: Old Danish Pointing Dogs have a *CHAT* missense variant (OMIA 000685‐9615) (Proschowsky *et al*. [2007](#age12350-bib-0026){ref-type="ref"}) and Brahman cattle have a *CHRNE* deletion (OMIA 000685‐9913) (Kraner *et al*. [2002](#age12350-bib-0017){ref-type="ref"}), whereas Labrador retrievers are the only companion animal species with a naturally occurring *COLQ* variant causing a CMS (OMIA 001928‐9615) (Rinz *et al*. [2014](#age12350-bib-0029){ref-type="ref"}).

A congenital myopathy in cats with autosomal recessive inheritance has been defined in Devon Rex and Sphynx breeds (OMIA 001621‐9685) (Lievesley & Gruffydd‐Jones [1989](#age12350-bib-0019){ref-type="ref"}; Robinson [1992](#age12350-bib-0030){ref-type="ref"}; Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}). Affected cats present with passive ventroflexion of the head and neck, head bobbing, scapulae protrusion, megaesophagus, generalized muscle weakness and fatigability (Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}) (Video S1, Case 1 (Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"}); Video S2, Case 1 (Shelton *et al*. [2007](#age12350-bib-0034){ref-type="ref"})). Muscle biopsies from affected cats demonstrated variable pathological changes ranging from dystrophic features (Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}) to minimal abnormalities (Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"}). Weakness of an affected cat was exacerbated by dosing with edrophonium, a clue that the problem might be a CMS. Crystalline inclusions were reported in a single cat (Shelton *et al*. [2007](#age12350-bib-0034){ref-type="ref"}). In a Sphynx and Devon Rex with identical clinical presentations, reduced expression of *α*‐dystroglycan was noted, whereas *β*‐dystroglycan, sarcoglycans, laminin *α*2 and dystrophin were expressed at normal levels (Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"}).

To genetically localize the Devon Rex/Sphynx myopathy, a case--control genome‐wide association study was conducted. Seven affected Devon Rex and 19 healthy Devon Rex cats were genotyped on the Illumina Infinium feline 63K array. Case--control population substructure was evaluated with identity by descent (IBD) and samples clustering (multidimensional scaling) analyses using [plink]{.smallcaps} (Purcell *et al*. [2007](#age12350-bib-0027){ref-type="ref"}), as described previously (Gandolfi *et al*. [2012](#age12350-bib-0013){ref-type="ref"}) (Fig. [1](#age12350-fig-0001){ref-type="fig"}a). Two affected cats were full siblings, two samples had an IBD value of \~0.3 and the remaining three samples showed some relatedness (\~0.2). The most significantly associated SNP ID C2:144738996 on cat chromosome C2, the homolog to human chromosome 3, was at position C2:131,341,886 (*P* ~raw~ = 8.89e^−7^, Bonferroni correction = 0.04) of feline genome assembly 6.2 (Montague *et al*. [2014](#age12350-bib-0023){ref-type="ref"}) (Fig. [1](#age12350-fig-0001){ref-type="fig"}b, c), which is \~463‐Kb upstream of *COLQ*. A common homozygous haplotype of almost 5 Mb within all cases spanning from position C2:128 192 494--131 992 072 contained 31 annotated genes (Fig. S1).

![Multidimensional scaling and Manhattan plot of the myopathy genome‐wide association study (GWAS). (a) Multidimensional scaling illustrating the distribution in two dimensions of the cases and controls of the Devon Rex used in the GWAS. The GWAS genomic inflation (ʎ) was 1.68. Although the detected population substructure is attributable to the relatedness between individuals, all samples were kept in the analysis due to the low number of available cases. Population stratification can confound a study, resulting in both false‐positive and false‐negative results. False results can be corrected using Bonferroni adjustment for multiple comparison and permutation testing analyses (see below). (b) Manhattan plot summarizing the case--control GWAS for myopathy cats. The most significantly associated SNPs were on cat chromosome C2 at positions 131 341 886 and 132 070 766; *COLQ* was located within the two highest SNP associations. (c) Bonferroni‐corrected values of each SNP included in the case--control study. Variant at position 131 341 886 on chromosome C2 remained significant after Bonferroni correction (0.04) (−log~10~ 1.4) and almost attains genome‐wide significance after 100 000 permutations (*P* ~*genome*~ value = 0.13).](AGE-46-711-g001){#age12350-fig-0001}

As part of the 99 Lives Cat Genome Sequencing Initiative ([www.felinegenetics.missouri.edu/99Lives](http://www.felinegenetics.missouri.edu/99Lives)), one Devon Rex cat with myopathy (Case 1; Shelton *et al*. [2007](#age12350-bib-0034){ref-type="ref"})) was whole‐genome sequenced. Two bar‐coded PCR‐free libraries (350 and 550 bp) were prepared using Illumina\'s TruSeq DNA PCR‐Free sample preparation kit (\#FC‐121‐3001), pooled and sequenced on a HiSeq 2000 (Illumina), generating paired‐end 100‐base reads to a genome depth of 20X. Reads were demultiplexed, trimmed with [trimmomatic]{.smallcaps} (Bolger *et al*. [2014](#age12350-bib-0003){ref-type="ref"}) and aligned to the *Felis catus* 6.2 genome (<http://www.ncbi.nlm.nih.gov/assembly/320798>) with BWA‐MEM (Li & Durbin [2009](#age12350-bib-0018){ref-type="ref"}). Duplicates were marked with [samblaster]{.smallcaps} (Faust & Hall [2014](#age12350-bib-0011){ref-type="ref"}), and variants were called with [platypus]{.smallcaps} (Rimmer *et al*. [2014](#age12350-bib-0028){ref-type="ref"}). Variant effects were predicted with [snpeff]{.smallcaps} (Cingolani *et al*. [2012](#age12350-bib-0004){ref-type="ref"}) based on Ensembl gene model release 75 (Cunningham *et al*. [2015](#age12350-bib-0005){ref-type="ref"}). Candidate variants genome wide and in the region of association and their depth of coverage were identified using dynamic filters based on phenotype‐specific allele frequencies in the Variant Explorer tool on the [maverix analytic platform]{.smallcaps} ([maverixbio.com](http://maverixbio.com)) and viewed using the UCSC Genome Browser (Rosenbloom *et al*. [2015](#age12350-bib-0031){ref-type="ref"}).

Considering SNP effects and their impacts (Table S2), only five moderate impact variants in three different genes (*TOPBP1*,*NPHP3* and *COLQ*) were detected within the associated haplotype, unique to the affected sequenced cat and wild type in a sequence database of 18 additional healthy cats of different breeds. *COLQ* (C2:131 805 630--131 863 452) represented the only candidate gene in the region, and only one missense mutation (c.1190G\>A at position 131 809 279 of chromosome C2) was identified within the gene coding region, suggesting the cat as a model for CMS. The publicly available *COLQ* sequence ([www.ensembl.org](http://www.ensembl.org)) more likely has exon 1 annotated incorrectly; using the human exon 1 sequence, the feline sequence was retrieved using the NCBI 'trace archive' tool (<http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&BLAST_SPEC=TraceArchive&PAGE_TYPE=BlastSearch&PROG_DEFAULTS=on>). The exon 1 sequence is included in the latest version of the genome assembly (position on chromosome C2: 131 863 337--131 863 442), and reads from all cats were aligned to the reference genome by [maverix]{.smallcaps}. No additional mutations segregating with the phenotype were detected in exon 1. *In silico* sequence translation of feline wild‐type *COLQ* generated from the 1368‐bp coding sequence (CDS) predicted a length of 455 amino acids. The predicted alignment suggests 88.4% identity to human *COLQ* (Fig. S2). To further correlate the identified variant with disease, 627 cats were genotyped by direct Sanger‐based sequencing or an allele‐specific assay, as described previously (Bighignoli *et al*. [2007](#age12350-bib-0002){ref-type="ref"}; Gandolfi *et al*. [2012](#age12350-bib-0013){ref-type="ref"}) (Table [1](#age12350-tbl-0001){ref-type="table-wrap"}, Table S1, Table S3). Eighteen affected cats were homozygous for the variant, including DNA isolated from formalin‐fixed paraffin‐embedded samples of the originally described affected Devon Rex cats (Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}), case 1 with inclusion bodies (Shelton *et al*. [2007](#age12350-bib-0034){ref-type="ref"}) and cases 1 and 2 (four cats) with the *α*‐dystroglycan deficiency (Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"}). To estimate the variant frequency in the Devon Rex and Sphynx breeds, 202 Devon Rex and 217 Sphynx that were submitted for DNA typing of coat colors (i.e. not associated with the disease study) were genotyped. Eight Devon Rex and one Sphynx were heterozygotes, and none were homozygous for the *COLQ* variant, implying allele frequencies of \~ 2.0% for Devon Rex and 0.2% for Sphynx, a breed that has allowable outcrosses to Devon Rex (Gandolfi *et al*. [2010](#age12350-bib-0012){ref-type="ref"}). The variant was absent in 168 cats from 26 different breeds (Table S1). The disease was first identified in the Devon Rex, and the higher allele frequency suggests the variant originated in this breed.

###### 

*COLQ* c.1190A\>G *ge*notypes in domestic cats breeds

  Type[a](#age12350-note-0001){ref-type="fn"}   Population   No.   Wild type (C/C)   Carrier (C/T)   Affected (T/T)
  --------------------------------------------- ------------ ----- ----------------- --------------- ----------------
  Biased                                        Devon Rex    40    17                5               18
  Unbiased                                      Devon Rex    202   194               8 (1.8%)        0
  Sphynx                                        217          216   1 (0.2%)          0               
  Other breeds (26)                             168          168   0                 0               
  Subtotal                                      587          578   9                 0               
  Total                                                      627   595               14              18

Type implies if the cat samples were 'biased' because of collection as part of the disease study versus 'unbiased' because the laboratory conducted a population screen of samples submitted for other genetic tests (typically coat color). Biased‐affected cats include the cats from all three publications (Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}; Shelton *et al*. [2007](#age12350-bib-0034){ref-type="ref"}; Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"}). Four of five sampled cats from Malik *et al*. ([1993](#age12350-bib-0020){ref-type="ref"}) were successfully genotyped from formalin‐fixed paraffin‐embedded muscle specimens.
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*COLQ* encodes the collagenous tail of acetylcholinesterase, the enzyme that terminates signal transduction at the neuromuscular junction (Cartaud *et al*. [2004](#age12350-bib-0500){ref-type="ref"}; Kimbell *et al*. [2004](#age12350-bib-0016){ref-type="ref"}). *COLQ* has three domains: an N‐terminal proline‐rich attachment domain (PRAD), a collagen central domain and a C‐terminal domain. The ColQ strand is attached to an AChE tetramer by the PRAD domain, whereas the collagen and C‐terminal domains assemble the triple helix (Ohno *et al*. [2000](#age12350-bib-0025){ref-type="ref"}). Moreover, the C‐terminal domain anchors the structure to the muscle cell membrane basal lamina (Kimbell *et al*. [2004](#age12350-bib-0016){ref-type="ref"}) that includes association with the *α*‐dystroglycan complex (Rotundo *et al*. [2005](#age12350-bib-0032){ref-type="ref"}; Sigoillot *et al*. [2010](#age12350-bib-0035){ref-type="ref"}). This association may explain reduced expression of *α*‐dystroglycan observed in some cats (Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"}) as a downstream effect of *COLQ* variants.

Human patients with *COLQ* variants (OMIM 603034) are generally severely disabled from an early age, with respiratory difficulties and progressive involvement of the axial muscles leading to severe scoliosis and restrictive ventilatory deficit (Engel *et al*. [2003a](#age12350-bib-0007){ref-type="ref"}). This clinical presentation is similar in cats, which show lordosis rather than scoliosis. Cats generally succumb to the disease by food‐related asphyxiation or aspiration pneumonia referable to bulbar weakness (Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}; Shelton & Engvall [2005](#age12350-bib-0033){ref-type="ref"}). As more CMS cases are attributed to *COLQ* variants, the heterogeneity of the disease has proven to be substantial. The majority of *COLQ* variants associated with CMS are frameshift or nonsense mutations that truncate the protein distally to PRAD (Ohno *et al*. [2000](#age12350-bib-0025){ref-type="ref"}; Engel *et al*. [2003a](#age12350-bib-0007){ref-type="ref"}; Engel & Sine [2005](#age12350-bib-0006){ref-type="ref"}; Mihaylova *et al*. [2008](#age12350-bib-0022){ref-type="ref"}). *COLQ* missense variants in humans have been identified in all three domains (Mihaylova *et al*. [2008](#age12350-bib-0022){ref-type="ref"}; Engel *et al*. [2015](#age12350-bib-0010){ref-type="ref"}). The cat variant (c.1190G\>A) is associated with a cysteine to tyrosine substitution (p.Cys397Tyr) in the wild‐type protein within the C‐terminal domain (submitted NCBI SNP identifier 1791785835). In humans, missense changes have been noted at p.Cys386Ser, p.Arg410Gln and p.ARg410Pro, including a similar but upstream variant at p.Cys417Tyr as well as a nonsense variant at p.Gln371Xaa.

The wide phenotypic and genotypic spectrum of EP AChE deficiency has led to the discovery of several patients with an absence of classical clinical symptoms that complicate diagnoses, including absence of a multiple compound muscle action potential (CMAP) (Mihaylova *et al*. [2008](#age12350-bib-0022){ref-type="ref"}). Clinical findings were similarly variable in the cats of this report. Four genotyped cats \[two Devon Rex (Shelton *et al*. [2007](#age12350-bib-0034){ref-type="ref"}) and two Sphynxes (Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"})\], which all were considered affected, underwent electrodiagnostic testing, consisting of electromyography (EMG), motor and sensory nerve conduction velocity testing and repetitive nerve stimulation (RNS). EMG findings ranged from prolonged insertion to spontaneous activity (fibrillation potentials, positive sharp waves and complex repetitive discharges). Numerous complex repetitive discharges were found in the laryngeal muscles of one Sphynx. Although CMAP amplitudes were reduced in one cat, sensory nerve conduction velocity values were normal in all cats. All cats had a normal CMAP morphology, that is multiple CMAPs following a single stimulus were not observed. RNS results were variable: One Devon Rex and one Sphynx had no significant decrement (i.e. \<10%), another Devon Rex showed a mild decremental response whereas the other Sphynx decremented greatly (Fig. S3a). Edrophonium administration had no effect (Fig. S3b).

Identification of the *COLQ* variant associated with this feline CMS affords clinicians the opportunity of establishing a diagnosis via genetic testing in these breeds. Furthermore, owners and breeders can now easily identify carriers in the population. An accurate diagnosis increases available therapeutic options for affected cats, such as the use of drugs such as ephedrine.
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**Table S1** *COLQ* c.1190G\>A genotypes in domestic cat breeds
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**Table S2** WGS variants identified in 20× coverage of an affected Devon Rex.

###### 

Click here for additional data file.

###### 

**Table S3** PCR primers used for genotyping *COLQ* variant in cats.

###### 

Click here for additional data file.

###### 

**Figure S1** Haplotype comparison between cases and controls in the region of association.
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**Figure S2** *COLQ* CDS and protein sequence. Presented are the feline wild‐type and mutated CDS and amino acid *COLQ* sequences.
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**Figure S3** Decremental response to repetitive nerve stimulation at 3 Hz in an affected Sphynx cat.
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**Video S1** Sphynx cats with *COLQ* variant for congenital myasthenic syndrome (CMS). Affected cats present with passive ventroflexion of the head and neck, head bobbing, scapulae protrusion, megaesophagus, generalized muscle weakness and fatigability (Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}). The video represents the three Sphynx male siblings that demonstrated *α*‐dystroglycan deficiency ‐ Case 1 (Martin *et al*. [2008](#age12350-bib-0021){ref-type="ref"}). Each cat died of food‐related asphyxiation or aspiration;
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**Video S2** Devon Rex cat with *COLQ* variant for congenital myasthenic syndrome (CMS). Affected cats present with passive ventroflexion of the head and neck, head bobbing, scapulae protrusion, megaesophagus, generalized muscle weakness and fatigability (Malik *et al*. [1993](#age12350-bib-0020){ref-type="ref"}). The video represents the Devon Rex with milder disease and crystalline inclusion bodies in muscle biopsy specimens -- Case 1 (Shelton *et al*. [2007](#age12350-bib-0034){ref-type="ref"}). This cat was euthanized due to complications of a fibrosarcoma.
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